Crescent Biopharma (NASDAQ:CBIO – Get Free Report) and Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Volatility & Risk
Crescent Biopharma has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Crescent Biopharma and Lexeo Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crescent Biopharma | 1 | 0 | 4 | 1 | 2.83 |
| Lexeo Therapeutics | 1 | 0 | 7 | 1 | 2.89 |
Earnings and Valuation
This table compares Crescent Biopharma and Lexeo Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crescent Biopharma | $11.88 million | 38.87 | -$153.94 million | ($10.91) | -1.54 |
| Lexeo Therapeutics | N/A | N/A | -$99.96 million | ($1.45) | -3.48 |
Lexeo Therapeutics has lower revenue, but higher earnings than Crescent Biopharma. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Crescent Biopharma and Lexeo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crescent Biopharma | N/A | -103.44% | -88.19% |
| Lexeo Therapeutics | N/A | -47.48% | -41.72% |
Insider & Institutional Ownership
75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Lexeo Therapeutics beats Crescent Biopharma on 8 of the 12 factors compared between the two stocks.
About Crescent Biopharma
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
